-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FTggaED5Fiz46tSsm4GwOHmq+xo2uV0mVgYs7anApbAyZ9a1tdBGVHZRW6m90Zeo zbAeATPbEWnvs6dYro7Gcw== 0001010412-98-000212.txt : 19981111 0001010412-98-000212.hdr.sgml : 19981111 ACCESSION NUMBER: 0001010412-98-000212 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19981103 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 19981110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SANGUINE CORP CENTRAL INDEX KEY: 0000926287 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 954347608 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-24480 FILM NUMBER: 98741472 BUSINESS ADDRESS: STREET 1: 101 EAST GREEN ST STREET 2: #11 CITY: PASADENA STATE: CA ZIP: 91105 BUSINESS PHONE: 8184050079 MAIL ADDRESS: STREET 1: 101 EAST GREEN ST STREET 2: STE 11 CITY: PASADENA STATE: CA ZIP: 91105 8-K 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20509 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act November 3, 1998 Date of Report (Date of Earliest Event Reported) SANGUINE CORPORATION (Exact Name of Registrant as Specified in its Charter) Nevada 0-24480 95-4347608 (State or other juris- (Commission File No.) (IRS Employer diction of incorporation) I.D. No.) 101 East Green Street, #11 Pasadena, California 91105 (Address of Principal Executive Offices) (626) 405-0079 Registrant's Telephone Number Item 1. Changes in Control of Registrant. None, not applicable. Item 2. Acquisition or Disposition of Assets. None, not applicable. Item 3. Bankruptcy or Receivership. None; not applicable. Item 4. Changes in Registrant's Certifying Accountant. None; not applicable. Item 5. Other Events. For information regarding specific Risk Factors regarding the Registrant's Business Operations and products, see the Registration Statement on Form 10-SB-A1, filed August 19, 1994, which is incorporated herein by reference. See Item 7, Exhibits. Item 6. Resignations of Registrant's Directors. None; not applicable. Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. Registration Statement on Form 10-SB-A1, filed August 19, 1994** ** This document and related exhibits has been previously filed with the Securities and Exchange Commission and is incorporated herein by reference. Exhibit Number Description - ------- ----------- 99 Press Release regarding synthetic blood substitute dated November 3, 1998 Item 8. Change in Fiscal Year. None; not applicable. SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. SANGUINE CORPORATION Date: 11/9/98 By:/s/Thomas C. Drees -------------------------------------- Thomas C. Drees CEO, President and Chairman of the Board of Directors Date: 11/9/98 By:/s/Anthony G. Hargreaves -------------------------------------- Anthony G. Hargreaves Vice President, Secretary/Treasurer and Director Date: 11/9/98 By:/s/David E. Nelson -------------------------------------- David E. Nelson CFO and Director EX-99 2 mkl pr [letterhead] IMMEDIATE RELEASE SANGUINE CORP. SCORES MAJOR SCIENTIFIC BREAKTHROUGH IN DEVELOPMENT OF SYNTHETIC BLOOD SUBST17FUTE Pasadena, CA. November 3, 1998. Sanguine Corporation (NASDAQ BB:SGNC) today released findings of a major scientific breakthrough in the development of its synthetic blood substitute, PHER-02. Research scientists in the current program for Sanguine at Battelle Memorial Institute (BMI) have developed five "novel" drug compounds to date that have "camouflage characteristics" which extend the effective fife of the compounds in the body and prevent the body from rejecting a synthetic substance. "The great significance of this breakthrough can not be overstated," commented Sanguine President and CEO Thomas C. Drees, Ph.D. "'Prior to this initial finding by Battelle, we already knew about 150 possible end use applications for PHER-02. This recent research suggests that the number of applications could be greatly expanded. Finally, this breakthrough improves the overall patentability of the product" Battelle's findings address problems found in earlier products as well as those of current competitor products, according to Drees. The limitation of short lifetime within the body would significantly restrict the type of procedures for which a blood substitute could be used. BMI chemists have conceived "novel" compounds that are expected to increase lifetimes in the bloodstream and allow the benefit of prolonged oxygen delivery to the patient. In its report to Sanguine, BMI also states its objective to establish the dates of Battelle's inventions and provide patent protection for the compounds and methodologies prepared and developed for Sanguine. Battelle is the world's largest independent contract research group of scientists, engineers, and other specialists. Its scientists have provided research since 1994 in support of Sanguine's efforts to develop, manufacture and market a proprietary synthetic red blood cell substitute. "Sanguine estimates the annual worldwide market potential for a synthetic red blood cell substitute at $20 billion," stated Drees. "In the United States, alone, nearly everyone who reaches the age of seventy-five will need blood, plasma, or one of their components at least once in his lifetime." Drees, who has been in the forefront of the artificial blood products field for more than twenty years, was the president and CEO of the only company to have obtained FDA approval for a synthetic blood product to date. For appropriate risk factors please refer to the 10SB Registration Statement previously filed by the company with the Securities & Exchange Commission at www.sec.gov. Contact: Steve Savage at (801) 328-8899 -----END PRIVACY-ENHANCED MESSAGE-----